LYRA THERAPEUTICS INC

Lyra Therapeutics is a clinical-stage biotechnology company whose primary product candidates, LYR-210 and LYR-220, are designed to treat chronic rhinosinusitis. The development pathway for these pharmaceutical candidates inherently involves animal testing to satisfy regulatory requirements for safety and efficacy prior to human clinical trials. This standard practice in drug development constitutes commercial exploitation of animals under the firm's exclusion policy.

The provided evidence searches returned no specific documentation of Lyra's animal testing protocols, violations, or scale. This is a common gap for pre-commercial biotech firms, as detailed laboratory practices are rarely disclosed in public SEC filings, which focus on financial and broad regulatory risks. The absence of explicit evidence does not negate the activity; animal testing is a foundational, non-optional component of bringing a new chemical entity like LYR-210 through the FDA review process. The company's business model is predicated on this exploitation.